Contribute Try STAT+ Today

The Sandoz unit of Novartis (NVS) is halting worldwide distribution of heartburn medicines containing high levels of a carcinogen and also issued a recall in some European countries and Canada.

The move comes as regulators scramble to understand why an impurity known as NDMA was found in the medicines, which are sold over the counter and by prescription. The same carcinogen was also detected last year in a class of blood pressure pills, prompting a spate of ongoing recalls, and these episodes have sparked broader concerns over the quality of the pharmaceutical supply chain.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • The terms ‘possible’ and ‘over a lifetime’ jumped out at me. Allowing that this is a potential carcinogen, I hear echos of the furor when it was realized that acetominaphine was not completely benign.
    More to come on this post, I am sure.

Comments are closed.